D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms - Wikidata - wikimedia - TriplyDB

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

http://www.wikidata.org/entity/Q27663612

about

sameAs

Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease In vitro selection of mutant HDM2 resistant to Nutlin inhibition Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography An Ultrahigh Affinity d -Peptide Antagonist Of MDM2 Motif mediated protein-protein interactions as drug targets A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity Computationally designed peptide inhibitors of the ubiquitin E3 ligase SCF(Fbx4).Delivery of mirror image polypeptides into cells Chemical genetics.Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.MDM2, MDMX and p53 in oncogenesis and cancer therapy A D-peptide analog of the second extracellular loop of claudin-3 and -4 leads to mislocalized claudin and cellular apoptosis in mammary epithelial cells.Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.Mirror image proteins.RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.Total chemical synthesis of human interferon alpha-2b via native chemical ligation How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined.Pooled screening for antiproliferative inhibitors of protein-protein interactions.Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation Probing the Sophisticated Synergistic Allosteric Regulation of Aromatic Amino Acid Biosynthesis in Mycobacterium tuberculosis Using ᴅ-Amino Acids Screening of a virtual mirror-image library of natural products.Large-Scale Interaction Profiling of Protein Domains Through Proteomic Peptide-Phage Display Using Custom Peptidomes.High-resolution structures of a heterochiral coiled coil Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury.Evaluation of Hydration Free Energy by Level-Set Variational Implicit-Solvent Model with Coulomb-Field Approximation.Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.Dephosphorylation of D-peptide derivatives to form biofunctional, supramolecular nanofibers/hydrogels and their potential applications for intracellular imaging and intratumoral chemotherapy.Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.Brahma-related gene 1 induces apoptosis in a p53-dependent manner in human rheumatoid fibroblast-like synoviocyte MH7A Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches.Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.Nutritional and medicinal aspects of D-amino acids.Recent advances in brain tumor-targeted nano-drug delivery systems.Stabilized helical peptides: overview of the technologies and therapeutic promises.

P2860

Q27305174-2F5C6A33-D776-4BEA-A5A1-6CC0B7E93810 Q27322456-0EF6B48B-E40A-4299-ABC3-9A6D9F67B572 Q27671712-672E6E7B-59CB-418C-BC99-8421C3B4A8CC Q27681154-17076901-C967-4E03-A851-49CFA4CFFEAD Q28079554-AF80D131-ECD1-4FEE-B6DE-C3C5E79AF9D7 Q28253043-1A8C4D25-BD14-41F2-ABE7-806D933E204C Q28481334-A584F2E4-C889-4EF4-9A5F-D2BF27D6AF60 Q28601353-5B0799B8-780C-460D-A511-FF978BFE95F0 Q33637957-C12148EA-97AA-4008-B8BF-BC9185C54717 Q33856364-F734E422-6C80-4221-B0E7-3F207377DAEC Q33896011-5A7EE24C-67A9-446D-A16C-4458FFF03867 Q34035617-5EE6F468-2B95-4FE1-9B0F-85175C808C17 Q34166049-20AF59F3-60B0-4BF0-9B31-E51110755536 Q34823180-3D0F417D-ADEE-407B-B4FE-749F82701AEF Q34973753-48991D7F-0DD7-42E3-B4A6-C1645479CEA9 Q35302104-77ADC2FF-8C29-4467-B148-19F1BC64CC8B Q35551978-19923F19-32D7-4A60-9F72-95A07493EA01 Q35587022-AEB298DC-FA8C-4CEB-A6EA-76BFC782F0A3 Q35871210-910B4A49-8008-4D41-B15F-D1047BBD04A5 Q35922756-FD4B9828-4978-464C-8CC0-B20634C59695 Q35930537-7909DF57-6417-4A89-AD05-AA230227B7D3 Q35950537-116D62CD-DFD2-42A5-A617-837081D3A434 Q36003370-EA6958E7-E34E-4ADE-9407-8E31E6DAB98A Q36023171-0B58F452-DB34-443C-8570-5A791CDBB125 Q36200688-7CCF873E-1638-44E8-8D77-2C9966775EF1 Q36238386-0176B298-880F-441E-A9A1-5A7068F38896 Q36329555-EF1D58D0-3155-4943-A3F4-775E74B0BD37 Q36374030-2A9A6690-C9B6-4B8A-81B1-DEC3EC8E83BC Q36682825-E95D5662-D69B-4982-9C44-7075F903729D Q37053063-41F80C86-C908-404B-AE08-82B072F93E84 Q37061570-62B57674-4A92-4856-883E-D5A9D714D0FF Q37168481-4CBFA9BD-AF3D-4AEF-A433-0D7AA71C4D75 Q37362651-BACB9410-2041-410D-A115-408DEBFC9BCB Q37490724-F7F5529C-6BE6-4F36-BE55-0A0F86BD39C3 Q37530496-AA8351D8-16D0-4A30-98B5-F90913817671 Q37651597-E0E21D15-6CD3-4132-8286-084D01CEE4F3 Q37689592-5DE92135-7DC4-4C2C-97B3-42A6CD714BB1 Q37868992-5C69C106-B644-4338-AB57-07F9C3ADAA6C Q38011262-460FF100-EA41-45B0-A8AF-C6B0552ED696 Q38014489-809310C7-E566-4E96-8E30-BF6B2D8547A3

P2860

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

http://www.wikidata.org/entity/Q27663612

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@nl

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@ast

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@en

type

label

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@nl

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@ast

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@en

prefLabel

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@nl

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@ast

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@en

P1433

Q27663612-358C7791-BE77-417F-9BF8-240E963D923C

P1476

Q27663612-DCCA6159-8430-4E06-8CD0-73AB9EAAF106

P2093

Q27663612-20492FF4-0861-4542-8918-C8F4A18DBB9F

Q27663612-29ABBD1F-BF14-479C-80D1-E9009BF07C80

Q27663612-3331C870-F856-45BB-867F-920706D4CE88

Q27663612-38899FAC-0F12-47DA-AC43-73C07092F15A

Q27663612-43686823-93BC-4843-A93E-F31C207482DA

Q27663612-5BD697C1-05BB-4393-BDC5-6704F28649E4

Q27663612-642EA79F-A62C-408B-BC72-09A9F3615E3D

Q27663612-717DC10C-72CC-496E-BAFE-9D2062C5018B

Q27663612-72183180-7FA5-41C7-ACAA-BC7D95941CB8

Q27663612-A2ADC8C6-7DC3-44EE-B34E-EE6490ABFA14

P2860

Q27663612-0466F848-9358-4D87-929F-B7231377FBF0

Q27663612-04C72233-1613-42D4-A679-BA4BC9B44492

Q27663612-06F1E64F-BFE8-4F5D-A939-27F3E91167F0

Q27663612-0A086B66-6B8B-45C8-9362-279DA59E3703

Q27663612-0F3CEA8E-D84C-49F7-8851-378951CD505F

Q27663612-14FE053E-2B35-46F3-809E-BF762E2BC059

Q27663612-16D70391-7826-4887-9EAC-D5BBAAF1B070

Q27663612-1EDBB0AF-5ECE-4DC6-8D69-6F3D8D578025

Q27663612-22BC8F76-0BD2-4BB3-936F-565ECB8C2CB6

Q27663612-24E8C909-76B9-42B7-9E2C-AD5C24E403EA

P304

Q27663612-666E1D3B-FF26-4F56-B4E6-08726FA9C7A3

P31

Q27663612-A3E70F43-73B9-4107-9F10-14947EA2842F

P3181

Q27663612-72E10125-E49E-40AB-AFF4-F2B7CC299FA4

P356

Q27663612-994F8ABB-2BE5-4949-BF94-CFA3FDB56EA6

P407

Q27663612-D15D63C1-8106-40BD-B3A7-4F69C1B197BE

P433

Q27663612-EA7FE00A-A484-4BDE-A9D8-483E901CBE4A

P478

Q27663612-F0A1F61B-9D4F-46D6-A7A5-CFD4BFFBB56B

P50

Q27663612-275CEA29-F295-454C-A73B-31D9B2AEB5DD

Q27663612-3AD0A941-420F-4DF1-B0CC-954BE8720AD4

Q27663612-843FEB3C-A890-4915-8760-74C291825D67

P577

Q27663612-FEB5F3F1-E37C-4D8A-9A05-7EE25646F376

P5875

Q27663612-CFBBEDDF-C9D1-41DD-986A-879F5C3B47DC

P698

Q27663612-99BB6EB7-4B43-4B5B-9C2C-C0BC10425526

P932

Q27663612-B9EC2369-2C75-4C05-A7E1-12654D7B3481

P3181

P356

PNAS.1008930107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

D-peptide inhibitors of the p5 ...... therapy of malignant neoplasms

@en

P2093

Bing Gu

http://www.w3.org/2001/XMLSchema#string

Changqing Li

http://www.w3.org/2001/XMLSchema#string

Changyou Zhan

http://www.w3.org/2001/XMLSchema#string

Chong Li

http://www.w3.org/2001/XMLSchema#string

Marzena Pazgier

http://www.w3.org/2001/XMLSchema#string

Wei-Yue Lu

http://www.w3.org/2001/XMLSchema#string

Weirong Yuan

http://www.w3.org/2001/XMLSchema#string

Wuyuan Lu

http://www.w3.org/2001/XMLSchema#string

Yifan Lv

http://www.w3.org/2001/XMLSchema#string

Yubin Mao

http://www.w3.org/2001/XMLSchema#string

P2860

Total chemical synthesis of proteins

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site

The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

Mdm2 promotes the rapid degradation of p53

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

Direct inhibition of the NOTCH transcription factor complex

P304

14321-14326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1996852

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1008930107

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45366335

http://www.w3.org/2001/XMLSchema#string

P698

20660730

http://www.w3.org/2001/XMLSchema#string

P932

2922601

http://www.w3.org/2001/XMLSchema#string